drugset / Trial / NCT05313152
Study of TAVO103A in Healthy Volunteers
RandomizedParallel-groupDouble-blindPrevention
Summary
This is a Phase 1, single ascending dose study designed to investigate TAVO103A, administered as an IV infusion up to 60 minutes in length to healthy adult subjects. This study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAVO103A.
Timeline
- Start
- 2022-04-05
- Primary completion
- 2023-04-26
- Completion
- 2023-06-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TAVO103A | Unknown | — | Intravenous |
Indications
No indication recorded.